The efficiency of a novel delivery system (PEI600-Tat) in development of potent DNA vaccine using HPV16 E7 as a model antigen

References

• Dubensky TW, Liu MA, Ulmer JB. (2000). Delivery systems for gene-based vaccines. Molec Med, 6, 723–32.
   PubMed Web of Science ®Google Scholar
• Hellgren I, Gorman J, Sylven C. (2004). Factors controlling the efficiency of Tat-mediated plasmid DNA transfer. J Drug Target, 12, 39–47.
   PubMed Web of Science ®Google Scholar
• Jarver P, Langel U. (2004). The use of cell-penetrating peptides as a tool for gene regulation. DDT, 9, 395–402.
   PubMed Web of Science ®Google Scholar
• Zorko M, Langel U. (2005). Cell-penetrating peptides: mechanism and kinetics cargo delivery. Adv Drug Deliv Rev, 57, 529–45.
   PubMed Web of Science ®Google Scholar
• Gupta B, Levchenko TS, Torchilin VP. (2005). Intracellular delivery of large molecules and small particles by cell-penetrating proteins and peptides. Adv Drug Deliv Rev, 57, 637–51.
   PubMed Web of Science ®Google Scholar
• Noguchi H, Matsumoto S. (2006). Protein transduction technology: a novel therapeutic perspective. Acta Med, 60, 1–11.
   Web of Science ®Google Scholar
• Wagstaff KM, Jans DA. (2006). Protein transduction: cell penetrating peptides and their therapeutic applications. Curr Med Chem, 13, 1371–87.
   PubMed Web of Science ®Google Scholar
• Martin ME, Rice KG. (2007). Peptide-guided gene delivery. The AAPS J, 9, E18–29.
   PubMed Web of Science ®Google Scholar
• Brooks H, Lebleu B, Vives E. (2005). Tat peptide-mediated cellular delivery: back to basics. Adv Drug Deliv Rev, 57, 559–77.
   PubMed Web of Science ®Google Scholar
• Tung CH, Mueller S, Weissleder R. (2002). Novel branching membrane translocational peptide as gene delivery vector. Bioorg Med Chem, 10, 3609–14.
   PubMed Web of Science ®Google Scholar
• Ignatovich IA, Dizhe EB, Pavlotskaya AV, Akifiev BN, Burov SV, Orlov SV, Perevozchikov AP. (2003). Complexes of plasmid DNA with basic domain 47–57 of the HIV-1 Tat protein are transferred to mammalian cells by endocytosis-mediated pathways. J Biol Chem, 278, 42625–36.
   PubMed Web of Science ®Google Scholar
• Riedl P, Reimann J, Schirmbeck R. (2004). Peptides containing antigenic and cationic domains have enhanced, multivalent immunogenicity when bound to DNA vaccines. J Mol Med, 82, 144–52.
   PubMed Web of Science ®Google Scholar
• Dizhe EB, Ignatovich IA, Burov SV, Pohvoscheva AV, Akifiev BN, Efremov AM, Perevozchikov AP, Orlov SV. (2006). Complexes of DNA with cationic peptides: conditions of formation and factors effecting internalization by mammalian cells. Biochemistry, 71, 1350–6.
   PubMed Web of Science ®Google Scholar
• Alexis F, Lo SL, Wang S. (2006). Covalent attachment of low molecular weight poly (ethyleneimine) improves Tat peptide mediated gene delivery. Adv Mater, 18, 2174–8.
   Web of Science ®Google Scholar
• Wang S. (2006). Tat peptide conjugates of low molecular weight polyethylenimine as effective non-viral gene delivery vectors. Molec Ther, 13, S76.
   Web of Science ®Google Scholar
• Boussif O, Lezoualch F, Zanta MA, Mergny MD, Scherman D, Demeneix B, Behr JP. (1995). A versatile vector for gene and oligonucleotide transfer into cells in culture and in vivo: polyethylenimine. Proc Natl Acad Sci, 92, 7297–301.
   PubMed Web of Science ®Google Scholar
• Godbey WT, Wu KK, Mikos AG. (1999). Poly (ethylenimine) and its role in gene delivery. J Contr Rel, 60, 149–60.
   PubMed Web of Science ®Google Scholar
• Putnam D, Gentry CA, Pack DW, Langer R. (2001). Polymer-based gene delivery with low cytotoxicity by a unique balance of side-chain termini. Proc Natl Acad Sci, 98, 1200–5.
   PubMed Web of Science ®Google Scholar
• Tang GP, Guo HY, Alexis F, Wang X, Zeng S, Lim TM, Ding J, Yang YY, Wang S. (2006). Low molecular weight polyethylenimines linked by β-cyclodextrin for gene transfer into the nervous system. J Gene Med, 8, 736–44.
   PubMed Web of Science ®Google Scholar
• Hausen HZ, Villiers EMD. (1994). Human papillomaviruses. Ann Rev Microbiol, 48, 427–47.
   PubMed Web of Science ®Google Scholar
• Schiller J, Davies P. (2004). Delivering on the promise: HPV vaccines and cervical cancer. Nature Rev, 2, 343–7.
   Web of Science ®Google Scholar
• Damania B. (2006). DNA tumor viruses and human cancer. Trends Microbiol, 15, 38–44.
   PubMed Web of Science ®Google Scholar
• Yan Q, Cheung YK, Cheng SC, Xian-Hua W, Yong X. (2007). A DNA vaccine constructed with human papillomavirus type 16 (HPV16) E7 and E6 genes induced specific immune responses. Gynecol Oncol, 104, 199–206.
   PubMed Web of Science ®Google Scholar
• Bolhassani A, Zahedifard F, Taghikhani M, Rafati S. (2008). Enhanced immunogenicity of HPV16E7 accompanied by Gp96 as an adjuvant in two vaccination strategies. Vaccine, 26, 3362–70.
   PubMed Web of Science ®Google Scholar
• Chen CH, Wang TL, Hung CF, Yang Y, Young R, Pardoll D, Wu TC. (2000). Enhancement of DNA vaccine potency by linkage of antigen gene to an HSP70 gene. Cancer Res, 60, 1035–42.
   PubMed Web of Science ®Google Scholar
• Leitner WW, Hammerl P, Thalhamer J. (2001). Nucleic acid for the treatment of cancer: Genetic vaccines and DNA adjuvants. Curr Pharm Des, 7, 1641–67.
   PubMed Web of Science ®Google Scholar
• Doria-Rose NA, Haigwood NL. (2003). DNA vaccine strategies: candidates for immune modulation and immunization regimens. Methods, 31, 207–16.
   PubMed Web of Science ®Google Scholar
• Lewis J. (2004). Therapeutic cancer vaccines: using unique antigens. PNAS, 101, 14653–6.
   PubMed Web of Science ®Google Scholar
• Kim TY, Myoung HJ, Kim JH, Moon IS, Kim TG, Ahn WS, Sin JI. (2002). Both E7 and CpG oligodeoxynuclotide are required for protective immunity against challenge with human papillomavirus 16 (E6/E7) immortalized tumor cells: involvement of CD4+ and CD8+ T cells in protection. Cancer Res, 62, 7234–40.
   PubMed Web of Science ®Google Scholar
• Michel N, Osen W, Gissmann L, Schumacher TNM, Zentgraf H, Muller M. (2002). Enhanced immunogenicity of HPV16 E7 fusion proteins in DNA vaccination. Virology, 294, 47–59.
   PubMed Web of Science ®Google Scholar
• Giannouli C, Brulet JM, Gesche F, Rappaport J, Burny A, Leo O, Hallez S. (2003). Fusion of a tumor-associated antigen to HIV-1 Tat improves protein-based immunotherapy of cancer. Anticancer Res, 23, 3523–32.
   PubMed Web of Science ®Google Scholar
• Li H, Ou X, Xiong J. (2007). Modified HPV16 E7/HSP70 DNA vaccine with high safety and enhanced cellular immunity represses murine lung metastatic tumors with downregulated expression of MHC class I molecules. Gynecol Oncol, 104, 564–71.
   Google Scholar
• Huang CY, Chen CA, Lee CN, Chang MC, Cheng WF. (2007). DNA vaccine encoding heat shock protein 60 co-linked to HPV16 E6 and E7 tumor antigens generates more potent immunotherapeutic effects than respective E6 or E7 tumor antigens. Gynecol Oncol, 107, 404–12.
   PubMed Web of Science ®Google Scholar
• Kim D, Gambhira R, Karanam B, Monie A, Hung CF, Roden R, Wu TC. (2008). Generation and characterization of a preventive and therapeutic HPV DNA vaccine. Vaccine, 26, 351–60.
   PubMed Web of Science ®Google Scholar
• Kim DT, Mitchell DJ, Brockstedt DG, Fong L, Nolan GP, Fathman CG, Engleman EG, Rothbard JB. (1997). Introduction of soluble proteins into the MHC class I pathway by conjugation to an HIV tat peptide. J Immunol, 159, 1666–8.
   PubMed Web of Science ®Google Scholar
• Riedl P, Buschle M, Reimann J, Schirmbeck R. (2002). Binding immune-stimulating oligonucleotides to cationic peptides from viral core antigen enhances their potency as adjuvants. Eur J Immunol, 32, 1709–16.
   PubMed Web of Science ®Google Scholar
• Riedl P, Reimann J, Schirmbeck R. (2004). Complexes of DNA vaccines with cationic, antigenic peptides are potent, polyvalent CD8+ T cell-stimulating immunogens. Methods Molec Med, 127, 159–69.
   Google Scholar
• Kleemann E, Neu M, Jekel N, Fink L, Schmehl T, Gessler T, Seeger W, Kissel T. (2005). Nano-carriers for DNA delivery to the lung based upon a Tat-derived peptide covalently coupled to PEG-PEI. J Contr Rel, 109, 299–316.
   PubMed Web of Science ®Google Scholar